Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Standard
Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. / Kellner, Michael; Muhtz, Christoph; Stark, Kristina; Yassouridis, Alexander; Arlt, Josef; Wiedemann, Klaus.
In: PSYCHOPHARMACOLOGY, Vol. 179, No. 1, 1, 01.04.2005, p. 310-315.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
AU - Kellner, Michael
AU - Muhtz, Christoph
AU - Stark, Kristina
AU - Yassouridis, Alexander
AU - Arlt, Josef
AU - Wiedemann, Klaus
PY - 2005/4/1
Y1 - 2005/4/1
N2 - RATIONALE: Preclinical findings have repeatedly shown an anxiolytic-like action of agonists at metabotropic glutamate receptors type II, such as LY354740.OBJECTIVE: We aimed to investigate the effect of LY544344, the prodrug of LY354740, upon experimental panic anxiety in humans.METHODS: Twelve healthy human volunteers were treated orally with 80 mg bid LY544344 for 1 week in a randomized placebo-controlled cross-over study before 50 mug cholecystokinin tetrapeptide (CCK-4) was injected intravenously. We assessed CCK-induced panic and anxiety symptoms and measured stress hormone release.RESULTS: While no significant treatment effect emerged in the entire sample, a significant reduction of the number of CCK-4-induced panic symptoms and of CCK-4-induced subjective anxiety ratings was detected after removing two subjects who did not show decreased CCK-4-elicited adrenocorticotropin (ACTH) release after LY544344 compared to placebo treatment.CONCLUSIONS: Further studies are needed to clarify the potential of LY544344 as a new anxiolytic or antipanic drug.
AB - RATIONALE: Preclinical findings have repeatedly shown an anxiolytic-like action of agonists at metabotropic glutamate receptors type II, such as LY354740.OBJECTIVE: We aimed to investigate the effect of LY544344, the prodrug of LY354740, upon experimental panic anxiety in humans.METHODS: Twelve healthy human volunteers were treated orally with 80 mg bid LY544344 for 1 week in a randomized placebo-controlled cross-over study before 50 mug cholecystokinin tetrapeptide (CCK-4) was injected intravenously. We assessed CCK-induced panic and anxiety symptoms and measured stress hormone release.RESULTS: While no significant treatment effect emerged in the entire sample, a significant reduction of the number of CCK-4-induced panic symptoms and of CCK-4-induced subjective anxiety ratings was detected after removing two subjects who did not show decreased CCK-4-elicited adrenocorticotropin (ACTH) release after LY544344 compared to placebo treatment.CONCLUSIONS: Further studies are needed to clarify the potential of LY544344 as a new anxiolytic or antipanic drug.
KW - Adrenocorticotropic Hormone
KW - Adult
KW - Anxiety
KW - Bicyclo Compounds
KW - Cross-Over Studies
KW - Double-Blind Method
KW - Excitatory Amino Acid Agonists
KW - Humans
KW - Hydrocortisone
KW - Male
KW - Panic Disorder
KW - Prolactin
KW - Receptors, Metabotropic Glutamate
KW - Tetragastrin
U2 - 10.1007/s00213-004-2025-1
DO - 10.1007/s00213-004-2025-1
M3 - SCORING: Journal article
C2 - 15821951
VL - 179
SP - 310
EP - 315
JO - PSYCHOPHARMACOLOGY
JF - PSYCHOPHARMACOLOGY
SN - 0033-3158
IS - 1
M1 - 1
ER -
